While the broader market remains fixated on tech mega-caps, I'm told that a quiet but significant overhaul is happening under the radar across specialized tech, biotech, and defensive ETFs. According to people familiar with the matter, this is the most significant reshuffling we've seen in these niches this year, driven by strategic mergers, executive moves, and macroeconomic positioning.

Levi Strauss & Co. (LEVI.US)

Shares of the iconic denim maker have been relatively resilient recently. In August 2026, the company disclosed a cybersecurity incident where an unauthorized third party accessed systems via a social engineering attack. However, I'm told the incident hasn't disrupted business operations. Before this, the company reported a solid Q2 2026, with adjusted EPS of USD 0.28 topping the USD 0.24 estimates and net revenues growing 8%.

Cellebrite DI (CLBT.US)

The digital investigation solutions provider has seen fluctuating shares lately as it heads toward its Q2 2026 earnings on August 13. According to filings, executive Thomas E. Hogan plans to sell some common stock this month through Morgan Stanley to cover tax withholding for vesting RSUs, though he retains over USD 9 million in shares. Meanwhile, the company expanded its exclusive partnership with SkySafe in July to bolster its drone detection capabilities.

Veritone (VERI.US)

Veritone has been under pressure this year, but it grabbed attention after joining the Russell 2000 and 3000 indexes in late June 2026. The enterprise AI software provider reported Q1 2026 revenue of USD 20.3M, missing estimates, though its EPS loss of USD 0.128 was better than expected. The company is pushing forward, recently rolling out a new AI-driven redaction suite and joining the Genesis task force to advance the US Department of Energy's national AI initiatives.

Jasper Therapeutics (JSPR.US)

The clinical-stage biotech firm saw significant movement recently. On July 16, 2026, the company announced an all-stock merger with Kira Pharmaceuticals. I'm told they plan a private placement to raise around USD 132M to fund the combined pipeline. This marks one of the most notable transactions in the space, as the new entity zeroes in on immune-driven diseases.

Bullfrog AI Holdings (BFRG.US)

The AI-driven biopharma company's shares have stabilized this year after it regained Nasdaq equity compliance in late April 2026. Earlier, Bullfrog AI announced a commercial feasibility agreement with a top-five global pharma company to use its bfLEAP platform for identifying targets in major depressive disorder. Expect this to be a key operational milestone before the next earnings.

JPMorgan Ultra-Short Income ETF (JPST.US)

This actively managed ultra-short bond ETF has been trading steadily. Reflecting ongoing demand for low-duration yield amid a shifting rate outlook, the fund amassed over USD 40.5B in AUM by early August 2026. It pulled in roughly USD 1.2B in net inflows in July alone, bringing its year-to-date inflows to over USD 5B.

Also

• Invesco DB Precious Metals Fund (DBP.US): With macro uncertainty lingering, this precious metals ETF continues to attract safe-haven bets, holding at relatively high levels this year.
• iShares Gold Trust Micro (IAUI.US): Similar to DBP, this micro gold trust is showing resilience, supported by shifting interest rate expectations.
• iShares TIPS Bond ETF (SUGP.US): The inflation-protected bond ETF is trading steadily as investors wait for the next key macroeconomic data print later this month.
• SK Telecom Co., Ltd. (SK.US): Trading volume for the Korean telecom giant has been light in the US, but I'm told management is preparing further updates on their global AI strategy later this year.

This article does not constitute investment advice.